4.2 Dyslipidemia & ASCVD Risk Calculation, Statin Therapy & Non-Statin Agents

Dyslipidemia & ASCVD Risk Calculation, Statin Therapy & Non-Statin Agents

Atherosclerotic Cardiovascular Disease (ASCVD)—encompassing coronary heart disease, ischemic stroke, transient ischemic attack (TIA), and peripheral artery disease (PAD)—remains the leading cause of death in adults. Apolipoprotein B-containing lipoproteins, particularly Low-Density Lipoprotein Cholesterol (LDL-C), penetrate injured arterial endothelium, undergo oxidative modification, trigger macrophage foam cell transformation, and drive progressive fibrofatty atheroma formation.

The 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol provides the clinical foundation for primary and secondary cardiovascular risk reduction. Board candidates must master the four statin benefit groups, 10-year ASCVD risk calculation, risk-enhancing factors, statin intensity stratifications, Coronary Artery Calcium (CAC) decision rules, non-statin add-on hierarchies, and the clinical management of statin-associated muscle symptoms (SAMS).

---

1. Lipoprotein Physiology, Lipid Panels & The Friedewald Equation

A standard fasting lipid profile measures Total Cholesterol (TC), High-Density Lipoprotein Cholesterol (HDL-C), and Triglycerides (TG), while calculating Low-Density Lipoprotein Cholesterol (LDL-C).

+-----------------------------------------------------------------------------+
|                        THE FRIEDEWALD EQUATION FOR LDL-C                    |
|                                                                             |
|                 \text{LDL-C} = \text{TC} - \text{HDL-C} - \frac{\text{TG}}{5}  |
|                                                                             |
|   * \frac{\text{TG}}{5} estimates Very Low-Density Lipoprotein (VLDL) cholesterol|
|   * VALIDITY CRITERION: Accurate ONLY when fasting Triglycerides < 400 mg/dL|
|   * LIMITATION: If TG >= 400 mg/dL, the Friedewald formula fails.           |
|     The AGPCNP must order a DIRECT LDL-C assay.                             |
+-----------------------------------------------------------------------------+

Clinical Lipid Fractions & Target Thresholds:

---

2. 10-Year ASCVD Risk Estimation & Risk-Enhancing Factors

For primary prevention in adults aged 40 to 75 years without diabetes and with LDL-C 70–189 mg/dL, clinical decision-making begins by calculating the 10-Year ASCVD Risk using the Pooled Cohort Equations (PCE). Variables include age, sex, race, total cholesterol, HDL-C, systolic blood pressure, treatment for hypertension, diabetes status, and current smoking history.

+-----------------------------------------------------------------------------+
|                 10-YEAR ASCVD RISK CATEGORIES (POOLED COHORT EQUATIONS)     |
|                                                                             |
|   RISK CATEGORY          10-YEAR RISK SCORE       PRIMARY CLINICAL RECOMMENDATION|
|   -----------------------------------------------------------------------   |
|   LOW RISK               < 5.0%                   Lifestyle modification    |
|   BORDERLINE RISK        5.0% to < 7.5%           Risk discussion; consider |
|                                                   moderate statin if risk   |
|                                                   enhancers present         |
|   INTERMEDIATE RISK      7.5% to < 20.0%          Moderate-intensity statin |
|                                                   (target: 30-49% reduction)|
|                                                   Consider CAC if uncertain |
|   HIGH RISK              >= 20.0%                 High-intensity statin     |
|                                                   (target: >= 50% reduction)|
+-----------------------------------------------------------------------------+

ASCVD Risk-Enhancing Factors:

When clinical judgment is borderline or intermediate, the presence of ASCVD Risk-Enhancing Factors favors initiating or intensifying statin therapy:

1. Family history of premature ASCVD (first-degree male relative $<55$ years, female relative $<65$ years).
2. Primary hypercholesterolemia (persistently elevated LDL-C $160–189\text{ mg/dL}$ or non-HDL $190–219\text{ mg/dL}$).
3. Metabolic Syndrome (presence of $\ge 3$: increased waist circumference, $\text{TG} \ge 150$, low HDL, $\text{BP} \ge 130/85$, fasting glucose $\ge 100$).
4. Chronic Kidney Disease (eGFR $15–59\text{ mL/min/1.73 m}^2$ with or without albuminuria; not treated with dialysis/transplant).
5. Chronic inflammatory conditions (Rheumatoid Arthritis, Systemic Lupus Erythematosus, Psoriasis, HIV/AIDS).
6. History of premature menopause (age $<40$ years) or pregnancy-associated conditions (Preeclampsia, Gestational Diabetes, low birth weight infant).
7. High-risk race/ethnicity (e.g., South Asian ancestry).
8. Persistently elevated inflammatory or lipid biomarkers:
   • High-sensitivity C-reactive protein ($\text{hs-CRP} \ge 2.0\text{ mg/L}$)
   • Lipoprotein(a) ($\text{Lp(a)} \ge 50\text{ mg/dL}$ or $\ge 125\text{ nmol/L}$)
   • Apolipoprotein B ($\text{ApoB} \ge 130\text{ mg/dL}$)
   • Ankle-Brachial Index ($\text{ABI} < 0.90$)

---

3. The Four Primary Statin Benefit Groups & Intensity Dosing

The 2018 AHA/ACC guidelines define four distinct patient populations where randomized clinical trial evidence demonstrates clear cardiovascular event reduction from statin therapy.

+-----------------------------------------------------------------------------+
|                     THE FOUR PRIMARY STATIN BENEFIT GROUPS                  |
|                                                                             |
|   GROUP 1: CLINICAL ASCVD (SECONDARY PREVENTION)                            |
|   - History of ACS, MI, Stable/Unstable Angina, Revascularization, Stroke,  |
|     TIA, or Peripheral Artery Disease of atherosclerotic origin.           |
|   - Age <= 75 years: HIGH-INTENSITY STATIN (Goal: >= 50% LDL-C reduction)   |
|   - Age > 75 years: Moderate- or High-Intensity Statin                      |
|   - Very High-Risk ASCVD: If LDL-C >= 70 on max statin -> Add EZETIMIBE;    |
|     If still >= 70 -> Add PCSK9 INHIBITOR                                   |
|                                                                             |
|   GROUP 2: SEVERE PRIMARY HYPERCHOLESTEROLEMIA (LDL-C >= 190 mg/dL)         |
|   - No risk score calculation needed; initiate HIGH-INTENSITY STATIN        |
|   - If LDL-C remains >= 100 mg/dL on max statin -> Add EZETIMIBE            |
|                                                                             |
|   GROUP 3: DIABETES MELLITUS IN ADULTS AGED 40-75 YEARS (LDL-C 70-189 mg/dL)|
|   - MODERATE-INTENSITY STATIN mandatory regardless of 10-year ASCVD score   |
|   - HIGH-INTENSITY STATIN indicated if multiple ASCVD risk factors or       |
|     10-year ASCVD risk >= 20%                                               |
|                                                                             |
|   GROUP 4: PRIMARY PREVENTION ACROSS LIFESPAN (AGED 40-75, LDL-C 70-189)    |
|   - 10-Yr Risk >= 20% (High Risk) -> HIGH-INTENSITY STATIN                  |
|   - 10-Yr Risk 7.5% to <20% (Intermediate) -> MODERATE-INTENSITY STATIN     |
|   - 10-Yr Risk 5% to <7.5% (Borderline) -> Discuss Moderate Statin if       |
|     risk-enhancing factors present                                          |
+-----------------------------------------------------------------------------+

Statin Intensity Stratification & Dosing Protocol

[!IMPORTANT] Definition of Very High-Risk ASCVD: Very High Risk is defined as a history of multiple major ASCVD events (e.g., recent ACS within 12 months, history of MI, ischemic stroke, symptomatic PAD) OR 1 major ASCVD event PLUS multiple high-risk conditions (e.g., age $\ge 65$, diabetes mellitus, hypertension, CKD, current smoking, persistently elevated $\text{LDL-C} \ge 100\text{ mg/dL}$, history of CHF). In these patients, the treatment threshold is $\text{LDL-C} < 70\text{ mg/dL}$ (or $<55\text{ mg/dL}$ per recent European updates); if $\text{LDL-C} \ge 70\text{ mg/dL}$ on maximum tolerated statin, add Ezetimibe, followed by a PCSK9 inhibitor.

---

4. Coronary Artery Calcium (CAC) Scoring in Clinical Decision-Making

In intermediate-risk patients ($7.5%$ to $<20%$) or selected borderline-risk patients ($5.0%$ to $<7.5%$) where the decision to initiate statin therapy remains uncertain, non-contrast cardiac CT for Coronary Artery Calcium (CAC) scoring provides definitive risk reclassification.

+-----------------------------------------------------------------------------+
|                      CORONARY ARTERY CALCIUM (CAC) ALGORITHM                |
|                                                                             |
|   [CAC SCORE = 0 (Agatston Units)]                                          |
|   - Excellent 10-year prognosis; low ASCVD event rate                       |
|   - WITHHOLD OR DELAY STATIN THERAPY (reassess in 5 years)                  |
|   - EXCEPTIONS (statin still favored despite CAC=0): Current cigarette      |
|     smokers, diabetes mellitus, family history of premature ASCVD          |
|                                                                             |
|   [CAC SCORE = 1 to 99 (or < 75th percentile for age/sex)]                  |
|   - Favors initiating MODERATE-INTENSITY STATIN therapy                      |
|   - Especially recommended if patient is age >= 55 years                    |
|                                                                             |
|   [CAC SCORE >= 100 (or >= 75th percentile for age/sex)]                    |
|   - HIGH-RISK EQUIVALENT: INITIATE STATIN THERAPY IMMEDIATELY               |
|   - Treat aggressively as high-risk primary prevention                      |
+-----------------------------------------------------------------------------+

---

5. Non-Statin Lipid-Lowering Pharmacotherapy

When maximally tolerated statin therapy fails to achieve LDL-C goals, or in cases of complete statin intolerance, non-statin agents are added in a stepwise, evidence-based sequence.

+-----------------------------------------------------------------------------+
|                    NON-STATIN PHARMACOLOGIC ARSENAL                         |
|                                                                             |
|   [STEP 1: FIRST-LINE ADD-ON]  ---> EZETIMIBE (10 mg daily)                 |
|                                     - Lowers LDL-C additional 15-20%        |
|                                     - Inexpensive, oral, well-tolerated     |
|                                           |                                 |
|                                           v                                 |
|   [STEP 2: SECOND-LINE ADD-ON] ---> PCSK9 INHIBITORS (Evolocumab/Alirocumab)|
|                                     - Lowers LDL-C additional 50-60%        |
|                                     - Injectable subQ q2w or monthly        |
|                                           |                                 |
|                                           v                                 |
|   [ALTERNATIVE & ADJUNCT AGENTS]                                           |
|   - Bempedoic Acid (ACL inhibitor; liver-specific prodrug, no myopathy)     |
|   - Bile Acid Sequestrants (Colesevelam; GI-bound, safe in pregnancy)       |
|   - Fibrates (Fenofibrate; PPAR-alpha agonist, primarily lowers TG)         |
|   - Omega-3 Fatty Acids (Icosapent Ethyl; lowers TG and ASCVD events)       |
+-----------------------------------------------------------------------------+

Detailed Pharmacology of Non-Statin Agents

---

6. Severe Hypertriglyceridemia Management & Pancreatitis Prevention

When fasting triglycerides reach or exceed $500\text{ mg/dL}$ (and especially $>1,000\text{ mg/dL}$), chylomicrons saturate capillary circulation in the pancreas, releasing excessive free fatty acids that overwhelm albumin binding, causing direct pancreatic capillary and acinar cell necrosis (Acute Hypertriglyceridemic Pancreatitis).

+-----------------------------------------------------------------------------+
|               HYPERTRIGLYCERIDEMIA CLINICAL MANAGEMENT PROTOCOL             |
|                                                                             |
|   [FASTING TRIGLYCERIDES 150 - 499 mg/dL] (MILD TO MODERATE)                |
|   - Primary goal: ASCVD Risk Reduction                                     |
|   - Maximize lifestyle: Weight loss, eliminate refined sugars, reduce alcohol|
|   - Optimize Statin therapy -> Add Icosapent Ethyl if indicated (REDUCE-IT) |
|                                                                             |
|   [FASTING TRIGLYCERIDES >= 500 mg/dL] (SEVERE)                             |
|   - PRIMARY IMMEDIATE GOAL: PREVENT ACUTE PANCREATITIS                      |
|   - LDL-C lowering is secondary until TG < 500 mg/dL                        |
|   - STRICT DIETARY INTERVENTION: Very low-fat diet (< 15% total calories),  |
|     complete abstinence from alcohol, avoid simple carbohydrates            |
|   - INITIATE FIBRATE THERAPY IMMEDIATELY: Fenofibrate 145 mg daily          |
|   - Consider adding Prescription Omega-3 Acid Ethyl Esters (4 g/day)        |
+-----------------------------------------------------------------------------+

---

7. Statin Safety, Muscle Symptoms (SAMS) & Monitoring Protocols

Statins (HMG-CoA reductase inhibitors) have an exceptional long-term safety profile. However, fear of side effects and Statin-Associated Muscle Symptoms (SAMS) represent the primary cause of medication non-adherence and discontinuation.

+-----------------------------------------------------------------------------+
|                      SPECTRUM OF STATIN-ASSOCIATED MYOPATHY                 |
|                                                                             |
|   [MYALGIA] (Common, 5-10%)                                                 |
|   - Muscle aches, soreness, stiffness, or weakness                          |
|   - Bilateral, proximal large muscle groups (thighs, calves, buttocks)      |
|   - Creatine Kinase (CK) level is NORMAL                                    |
|                                                                             |
|   [MYOSITIS / MYOPATHY] (Uncommon, <0.1%)                                   |
|   - Muscle pain and weakness accompanied by ELEVATED CK (3x-10x ULN)        |
|                                                                             |
|   [RHABDOMYOLYSIS] (Rare, 1 in 100,000)                                     |
|   - Severe muscle necrosis with CK > 10x to > 40x ULN                       |
|   - Myoglobinuria ("tea-colored" / dark brown urine)                        |
|   - Acute kidney injury from myoglobin tubular precipitation                 |
+-----------------------------------------------------------------------------+

Step-by-Step Clinical Protocol for SAMS Evaluation:

1. Baseline Assessment: Measure baseline ALT/AST and lipid panel prior to statin initiation. Routine baseline Creatine Kinase (CK) is not recommended unless the patient has pre-existing neuromuscular disease or takes interacting drugs.
2. Routine Surveillance: Recheck fasting lipid panel at 4 to 12 weeks post-initiation or dose adjustment to assess adherence and response, then every 3 to 12 months thereafter. Routine surveillance monitoring of liver function tests (LFTs) or CK in asymptomatic patients is not recommended.
3. Management of Reported Muscle Symptoms:
   • Step 1: Discontinue the statin temporarily (washout period of 2 to 4 weeks) until muscle symptoms completely resolve.
   • Step 2: Check serum CK, creatinine, and urinalysis for myoglobin if symptoms are severe or urine is dark.
   • Step 3: Once symptoms have fully resolved, re-challenge the patient with the same statin at a lower dose or switch to an alternative statin with different pharmacokinetic properties:
     • Switch from a lipophilic statin (atorvastatin, simvastatin, lovastatin) to a hydrophilic statin (rosuvastatin, pravastatin), which has lower muscle tissue penetration.
     • Utilize non-daily or intermittent dosing (e.g., Rosuvastatin 5–10 mg orally two to three times per week) due to its long elimination half-life (19 hours).
   • Step 4: If patient cannot tolerate any daily or intermittent statin dose, classify as statin-intolerant and initiate Ezetimibe and/or Bempedoic Acid or a PCSK9 inhibitor.